Yves Fougère
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yves Fougère has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Pierre Alex Crisinel
Unit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne , Lausanne
4 shared publications - Michael Buettcher
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
3 shared publications - Petra Zimmermann
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
3 shared publications - Anita Uka
Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
2 shared publications - Begoña Martinez de Tejada
Department of Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, Geneva, Switzerland
2 shared publications - Christian Raphael Kahlert
Division of Infectious Diseases, Kantonsspital St Gallen, St. Gallen, Switzerland
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Epidemiology, Early Therapy and Sequelae Predictors in Congenital CMV
Background: Congenital cytomegalovirus (cCMV) is the most common congenital infection, with approximately 17%–20% of infected neonates developing permanent sequelae. Early risk stratification remains challenging yet crucial for therapeutic decision-making. We aimed to characterize national epidemiology, identify early predictors of sequelae, and assess the impact of early antiviral treatment on outcomes in infants with cCMV. Methods: We conducted a nationwide prospective observational study between 2017 and 2024, analyzing birth and 1-year follow-up data of infants with confirmed cCMV in Switzerland. Results: Two hundred and nine cCMV-infected children were included. The most common findings at birth were microcephaly (35%), intrauterine growth restriction (34%) and neuroimaging abnormalities (36%). Antiviral treatment was administered to 36% (75/209) of patients, among whom 75% (56/75) had treatment initiation within the first month of life. Multivariate analysis identified hepatosplenomegaly (odds ratio 13.2, 95% confidence interval, 2.3–75.2) and hypotonia at birth (odds ratio 6.6, 95% confidence interval, 1.1–41.1) as independent predictors of late-onset sensorineural hearing loss (SNHL). At the 1-year follow-up assessment, early treatment initiation was associated with significantly lower rates of neurodevelopmental disorders compared with delayed treatment initiation (23% vs. 50%, P = 0.004). Conclusions: This Swiss nationwide study confirms the previously reported association between hepatosplenomegaly at birth and late-onset SNHL and identifies hypotonia as a new independent predictor of late-onset SNHL. The data also confirm the crucial role of early antiviral treatment, particularly for neurodevelopmental disorders, emphasizing the importance of prompt cCMV diagnosis and treatment when indicated.
- 21 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Open AccessEpidemiology, Early Therapy and Sequelae Predictors in Congenital CMV
Background: Congenital cytomegalovirus (cCMV) is the most common congenital infection, with approximately 17%–20% of infected neonates developing permanent sequelae. Early risk stratification remains challenging yet crucial for therapeutic decision-making. We aimed to characterize national epidemiology, identify early predictors of sequelae, and assess the impact of early antiviral treatment on outcomes in infants with cCMV. Methods: We conducted a nationwide prospective observational study between 2017 and 2024, analyzing birth and 1-year follow-up data of infants with confirmed cCMV in Switzerland. Results: Two hundred and nine cCMV-infected children were included. The most common findings at birth were microcephaly (35%), intrauterine growth restriction (34%) and neuroimaging abnormalities (36%). Antiviral treatment was administered to 36% (75/209) of patients, among whom 75% (56/75) had treatment initiation within the first month of life. Multivariate analysis identified hepatosplenomegaly (odds ratio 13.2, 95% confidence interval, 2.3–75.2) and hypotonia at birth (odds ratio 6.6, 95% confidence interval, 1.1–41.1) as independent predictors of late-onset sensorineural hearing loss (SNHL). At the 1-year follow-up assessment, early treatment initiation was associated with significantly lower rates of neurodevelopmental disorders compared with delayed treatment initiation (23% vs. 50%, P = 0.004). Conclusions: This Swiss nationwide study confirms the previously reported association between hepatosplenomegaly at birth and late-onset SNHL and identifies hypotonia as a new independent predictor of late-onset SNHL. The data also confirm the crucial role of early antiviral treatment, particularly for neurodevelopmental disorders, emphasizing the importance of prompt cCMV diagnosis and treatment when indicated.
- 18 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Unilateral Earlobe Edema in Acute Primary Epstein–Barr Virus Infection
Was not provided for this article.
- 18 September 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Unilateral Earlobe Edema in Acute Primary Epstein–Barr Virus Infection
Was not provided for this article.
- Open Access
- 9 January 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (2) , 106688
Infection-related mortality in children in two European countries, 2015–2023: An interrupted time-series analysis
- 9 January 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (2) , 106688
Open AccessInfection-related mortality in children in two European countries, 2015–2023: An interrupted time-series analysis
- Open Access
- 1 November 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (11) , 4537
Breastfeeding with HIV in a high-income setting: equipoise and beyond – time to question the zero-risk policy
With the use of combined antiretroviral therapy (cART), it has become possible to completely and permanently suppress human immunodeficiency virus (HIV) replication. Successful treatment with combined antiretroviral therapy not only makes HIV infection a treatable chronic disease with a near-normal life expectancy, but also reliably prevents horizontal and also vertical virus transmission. In principle, this allows us to dispense with certain preventive measures from the pre-cART era. However, HIV prevention recommendations tend not to be adjusted until it has been proven beyond any doubt that there is no associated risk. This zero-risk strategy still makes HIV infection a special case and contradicts standard medical practice, which almost always also entails some acceptable risk. This hesitant attitude delays adaptations of care and contributes to the stigmatisation of those affected. In addition, it might even violate the ethical principles of beneficence and justice. In this context, there is still an ongoing debate as to whether the credo “U = U” (undetectable = untransmittable) applies to all aspects of vertical transmission. While there is consensus about the safety of vaginal delivery in case of an undetectable maternal viral load, Switzerland is still the only country that has also refrained from providing post-exposure prophylaxis to newborns since 2016 in such cases. Furthermore, when we last revised our Swiss recommendations for the prevention of vertical transmission in 2018, we assumed a balance (equipoise) between the benefits and potential risks of breastfeeding with HIV under optimal conditions. We proposed a shared decision-making process to allow the expectant mother to make her own well-considered decision which is then unconditionally supported by the care team. However, the decision and the associated responsibility is basically left to the woman. Most high-income countries have meanwhile adopted this procedure. Based on a literature review summarised in this article, the question arises as to whether this approach is still justified. We came to the conclusion that the potential risks of breastfeeding with HIV are being overemphasised, as benefits of breastfeeding, including reductions in morbidity and mortality for both mother and child appear to clearly outweigh these apparently very low risks, even in high-income settings. We therefore believe that breastfeeding with HIV should be favoured and encouraged and not just supported under optimal circumstances and that the care teams should take a clear position in this regard. This will facilitate decision-making for affected women, reduce stigma, relieve the parent(s) of taking on primary responsibility for the decision and further “normalise” HIV infection.
- 1 November 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (11) , 4537
Open AccessBreastfeeding with HIV in a high-income setting: equipoise and beyond – time to question the zero-risk policy
With the use of combined antiretroviral therapy (cART), it has become possible to completely and permanently suppress human immunodeficiency virus (HIV) replication. Successful treatment with combined antiretroviral therapy not only makes HIV infection a treatable chronic disease with a near-normal life expectancy, but also reliably prevents horizontal and also vertical virus transmission. In principle, this allows us to dispense with certain preventive measures from the pre-cART era. However, HIV prevention recommendations tend not to be adjusted until it has been proven beyond any doubt that there is no associated risk. This zero-risk strategy still makes HIV infection a special case and contradicts standard medical practice, which almost always also entails some acceptable risk. This hesitant attitude delays adaptations of care and contributes to the stigmatisation of those affected. In addition, it might even violate the ethical principles of beneficence and justice. In this context, there is still an ongoing debate as to whether the credo “U = U” (undetectable = untransmittable) applies to all aspects of vertical transmission. While there is consensus about the safety of vaginal delivery in case of an undetectable maternal viral load, Switzerland is still the only country that has also refrained from providing post-exposure prophylaxis to newborns since 2016 in such cases. Furthermore, when we last revised our Swiss recommendations for the prevention of vertical transmission in 2018, we assumed a balance (equipoise) between the benefits and potential risks of breastfeeding with HIV under optimal conditions. We proposed a shared decision-making process to allow the expectant mother to make her own well-considered decision which is then unconditionally supported by the care team. However, the decision and the associated responsibility is basically left to the woman. Most high-income countries have meanwhile adopted this procedure. Based on a literature review summarised in this article, the question arises as to whether this approach is still justified. We came to the conclusion that the potential risks of breastfeeding with HIV are being overemphasised, as benefits of breastfeeding, including reductions in morbidity and mortality for both mother and child appear to clearly outweigh these apparently very low risks, even in high-income settings. We therefore believe that breastfeeding with HIV should be favoured and encouraged and not just supported under optimal circumstances and that the care teams should take a clear position in this regard. This will facilitate decision-making for affected women, reduce stigma, relieve the parent(s) of taking on primary responsibility for the decision and further “normalise” HIV infection.
- Open Access
- 5 October 2025
- Published by Elsevier in Clinical Infection in Practice
- Vol. 28
First case report of Rahnella bacteremia in a healthy child
- 5 October 2025
- Published by Elsevier in Clinical Infection in Practice
- Vol. 28
Open AccessFirst case report of Rahnella bacteremia in a healthy child
- Open Access
- 7 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (8) , 764-771
Clinical and Immunologic Impact of CMV Coinfection Among Children Living With HIV in Canada
Background: Although cytomegalovirus (CMV) disease has been well described among severely immunocompromised children living with HIV (CLWH), the impact of CMV coinfection, is not well understood. The objective of this study was to characterize the clinical and immunologic effects of CMV coinfection in CLWH in Canada. Methods: This is a substudy of the Early Pediatric Initiation, Canada Child Cure Cohort study, which enrolled CLWH in Canada between 2014 and 2018. CMV serostatus was determined at the first (baseline) study visit, and HIV-1 viral load (VL), CMV VL, and lymphocyte subsets were quantified every 3–6 months. For a subset of participants, CD4+ and CD8+ T cell subsets were analyzed using flow cytometry. The clinical outcomes were recorded retrospectively at the baseline visit and prospectively during the study period. Results: Of the 225 participants, 85.3% were CMV seropositive (CMV+) and 81% had suppressed HIV VL. While there were no significant differences in clinical outcomes between CMV+ and CMV− children, CMV+ children had lower frequencies of CD4+ T cells, higher frequencies of CD8+ T cells, and lower CD4/CD8 ratio at baseline than CMV− children. Children with CMV+ children also demonstrated a higher frequency of CD4+ effector memory cells, lower CD8+ naïve T cells, and higher frequencies of CD8+ terminally differentiated effector memory cells. These differences remained significant even after adjusting for HIV viral control. Conclusions: CMV coinfection is common among CLWH and is associated with distinct immunological changes despite the effective control of HIV replication with antiretroviral therapy. The long-term implications of these immunologic perturbations require further investigation.
- 7 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (8) , 764-771
Open AccessClinical and Immunologic Impact of CMV Coinfection Among Children Living With HIV in Canada
Background: Although cytomegalovirus (CMV) disease has been well described among severely immunocompromised children living with HIV (CLWH), the impact of CMV coinfection, is not well understood. The objective of this study was to characterize the clinical and immunologic effects of CMV coinfection in CLWH in Canada. Methods: This is a substudy of the Early Pediatric Initiation, Canada Child Cure Cohort study, which enrolled CLWH in Canada between 2014 and 2018. CMV serostatus was determined at the first (baseline) study visit, and HIV-1 viral load (VL), CMV VL, and lymphocyte subsets were quantified every 3–6 months. For a subset of participants, CD4+ and CD8+ T cell subsets were analyzed using flow cytometry. The clinical outcomes were recorded retrospectively at the baseline visit and prospectively during the study period. Results: Of the 225 participants, 85.3% were CMV seropositive (CMV+) and 81% had suppressed HIV VL. While there were no significant differences in clinical outcomes between CMV+ and CMV− children, CMV+ children had lower frequencies of CD4+ T cells, higher frequencies of CD8+ T cells, and lower CD4/CD8 ratio at baseline than CMV− children. Children with CMV+ children also demonstrated a higher frequency of CD4+ effector memory cells, lower CD8+ naïve T cells, and higher frequencies of CD8+ terminally differentiated effector memory cells. These differences remained significant even after adjusting for HIV viral control. Conclusions: CMV coinfection is common among CLWH and is associated with distinct immunological changes despite the effective control of HIV replication with antiretroviral therapy. The long-term implications of these immunologic perturbations require further investigation.
- Open Access
- 1 November 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (11) , 3678
Syphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study
BACKGROUND AND AIMS OF THE STUDY: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infantʼs subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis. METHODS: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records. RESULTS: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women’s risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19–0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81–617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022). CONCLUSION: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).
- 1 November 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (11) , 3678
Open AccessSyphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study
BACKGROUND AND AIMS OF THE STUDY: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infantʼs subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis. METHODS: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records. RESULTS: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women’s risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19–0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81–617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022). CONCLUSION: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (2) , e158-e164
Unexpected associations between respiratory viruses and bacteria with Pulmonary Function Testing in children suffering from Cystic Fibrosis (MUCOVIB study)
- 1 March 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (2) , e158-e164
Open AccessUnexpected associations between respiratory viruses and bacteria with Pulmonary Function Testing in children suffering from Cystic Fibrosis (MUCOVIB study)
- Open Access
- 29 November 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (3) , 1245-1255
Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study
Coronavirus disease 2019 (COVID-19) is usually less severe in children compared to adults. This study describes detailed clinical characteristics, treatment and outcomes of children with COVID-19 in a non-hospitalised and hospitalised setting and quantifies factors associated with admission to hospital and intensive care unit in children with SARS-CoV-2 infection on a nationwide level. Data were collected through the Swiss Paediatric Surveillance Unit from children < 18 years with confirmed SARS-CoV-2 infection. All 33 paediatric hospitals in Switzerland reported non-hospitalised and hospitalised cases from March 1 to October 31, 2020 during both pandemic peaks. In total, 678 children were included. The median age was 12.2 years (IQR 5.0–14.6), 316 (46.6%) were female and 106 (15.6%) had comorbidities. Overall, 126 (18.6%) children were hospitalised of whom 16 (12.7%) required ICU admission. Comorbidities were the only factor associated with hospital admission in a multivariable regression analysis (odds ratio 3.23, 95%CI 1.89 to 5.50;p-value < 0.01). Children with preexisting comorbidities did not require ICU admission more often. Hospitalised children more often presented with fever (96 [76.2%] vs 209 [38.1%],p-value < 0.01) and rash (16 [12.8%] vs 6 [1.1%],p-value < 0.01). Anosmia/dysgeusia was more prevalent in non-hospitalised children (73 [13.3%] vs 3 [2.4%],p-value < 0.01). In hospitalised children, oxygen treatment was required in 34 (27.0%), inotropes in nine (7.3%) and mechanical ventilation in eight (6.3%) cases. Complications were reported in 28 (4.1%) children with cardiovascular complications being most frequent (12 [1.8%]). Three deaths were recorded.Conclusion: This study confirms that COVID-19 is mostly a mild disease in children. Fever, rash and comorbidities are associated with higher admission rates. Continuous observation is necessary to further understand paediatric COVID-19, guide therapy and evaluate the necessity for vaccination in children. What is Known:• Clinical manifestations of SARS-CoV-2 infection in children vary from asymptomatic to critical disease requiring intensive care unit admission.• Most studies are based on hospitalised children only; currently, there is limited data on non-hospitalised children. What is New:• The clinical spectrum and severity of COVID-19 is influenced by age: in children less than 2 years, fever, cough and rhinorrhoea are the most common symptoms and in adolescents, fever, cough and headache are more common.• Hospitalised children more often presented with fever and rash, while anosmia/dysgeusia is more prevalent in non-hospitalised children.• Children with pre-existing comorbidities are more frequently hospitalised but do not require ICU admission more often.
- 29 November 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (3) , 1245-1255
Open AccessFactors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study
Coronavirus disease 2019 (COVID-19) is usually less severe in children compared to adults. This study describes detailed clinical characteristics, treatment and outcomes of children with COVID-19 in a non-hospitalised and hospitalised setting and quantifies factors associated with admission to hospital and intensive care unit in children with SARS-CoV-2 infection on a nationwide level. Data were collected through the Swiss Paediatric Surveillance Unit from children < 18 years with confirmed SARS-CoV-2 infection. All 33 paediatric hospitals in Switzerland reported non-hospitalised and hospitalised cases from March 1 to October 31, 2020 during both pandemic peaks. In total, 678 children were included. The median age was 12.2 years (IQR 5.0–14.6), 316 (46.6%) were female and 106 (15.6%) had comorbidities. Overall, 126 (18.6%) children were hospitalised of whom 16 (12.7%) required ICU admission. Comorbidities were the only factor associated with hospital admission in a multivariable regression analysis (odds ratio 3.23, 95%CI 1.89 to 5.50;p-value < 0.01). Children with preexisting comorbidities did not require ICU admission more often. Hospitalised children more often presented with fever (96 [76.2%] vs 209 [38.1%],p-value < 0.01) and rash (16 [12.8%] vs 6 [1.1%],p-value < 0.01). Anosmia/dysgeusia was more prevalent in non-hospitalised children (73 [13.3%] vs 3 [2.4%],p-value < 0.01). In hospitalised children, oxygen treatment was required in 34 (27.0%), inotropes in nine (7.3%) and mechanical ventilation in eight (6.3%) cases. Complications were reported in 28 (4.1%) children with cardiovascular complications being most frequent (12 [1.8%]). Three deaths were recorded.Conclusion: This study confirms that COVID-19 is mostly a mild disease in children. Fever, rash and comorbidities are associated with higher admission rates. Continuous observation is necessary to further understand paediatric COVID-19, guide therapy and evaluate the necessity for vaccination in children. What is Known:• Clinical manifestations of SARS-CoV-2 infection in children vary from asymptomatic to critical disease requiring intensive care unit admission.• Most studies are based on hospitalised children only; currently, there is limited data on non-hospitalised children. What is New:• The clinical spectrum and severity of COVID-19 is influenced by age: in children less than 2 years, fever, cough and rhinorrhoea are the most common symptoms and in adolescents, fever, cough and headache are more common.• Hospitalised children more often presented with fever and rash, while anosmia/dysgeusia is more prevalent in non-hospitalised children.• Children with pre-existing comorbidities are more frequently hospitalised but do not require ICU admission more often.